A BILL FOR AN ACT

RELATING TO LIFE SCIENCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature finds that the life sciences
- 2 industry plays a significant role in the diversification and
- 3 therefore, the sustainability of Hawaii's economy. Ground-
- 4 breaking medical studies have already been conducted in Hawaii
- 5 by the Cancer Research Center and Pacific Health Research
- 6 Institute.
- 7 Hawaii's unique location and ethnic diversity provide
- 8 indispensable advantages to companies conducting clinical
- 9 trials. Life sciences companies that conduct these trials often
- 10 create more and higher paying jobs that will help to keep our
- 11 local talent employed in the State. In addition, conducting
- 12 these trials in Hawaii will put our State on the cutting edge of
- 13 drug development, bringing in research funding from Asia and
- 14 North America.
- 15 Providing a specific tax boost would particularly help
- 16 Hawaii companies that are pioneering pharmaceutical and other

- 1 health products at a time that they are entering phases three 2 and four of their clinical trials. 3 The purpose of this Act is to advance the important specialization components of the Hawaii life sciences road map 4 by providing a tax incentive for life sciences companies to 5 conduct clinical trials in Hawaii. 6 SECTION 2. Chapter 235, Hawaii Revised Statutes, is 7 amended by adding a new section to be appropriately designated 8 9 and to read as follows: "§235- Clinical trials; income tax credit. (a) Any law 10 to the contrary notwithstanding, there shall be allowed to each 11 12 taxpayer subject to the taxes imposed by this chapter, an income tax credit that shall be deductible from the taxpayer's net 13 income tax liability, if any, imposed by this chapter for the 14 taxable year in which the credit is properly claimed. The 15 amount of the credit shall be: 16 (1) Fifteen per cent of the qualified clinical trial costs 17 18 incurred by a qualified clinical trial in any county of the State with a population of over seven hundred 19
- 21 (2) Twenty per cent of the qualified clinical trial costs

 22 incurred by a qualified clinical trial in any county

thousand; or

20

```
1
              of the State with a population of seven hundred
2
              thousand or less.
3
    A qualified clinical trial occurring in more than one county may
4
    prorate its expenditures based upon the amounts spent in each
5
    county; provided that the population bases differ enough to
6
    change the percentage of tax credit.
7
         In the case of a partnership, S corporation, estate, or
8
    trust, the tax credit allowable is for qualified clinical trial
9
    costs incurred by the entity for the taxable year. The cost
10
    upon which the tax credit is computed shall be determined at the
11
    entity level. Distribution and share of credit shall be
12
    determined by rule.
         If a deduction is taken under section 179 (with respect to
13
14
    election to expense depreciable business assets) of the Internal
    Revenue Code of 1986, as amended, no tax credit shall be allowed
15
    for those costs for which the deduction is taken. The basis for
16
17
    eligible property for depreciation of accelerated cost recovery
18
    system purposes for state income taxes shall be reduced by the
    amount of credit allowable and claimed.
19
         (b) The credit allowed under this section shall be claimed
20
    against the net income tax liability for the taxable year. For
21
    the purposes of this section, "net income tax liability" means
22
    2008-1059 SB3236 SD1 SMA.doc
```

1 net income tax liability reduced by all other credits allowed 2 under this chapter. 3 (c) If the tax credit under this section exceeds the taxpayer's income tax liability, the excess of credits over 4 liability shall be refunded to the taxpayer; provided that no 5 6 refunds or payment on account of the tax credits allowed by this 7 section shall be made for amounts less than \$1. All claims, including any amended claims, for tax credits under this section 8 9 shall be filed on or before the end of the twelfth month following the close of the taxable year for which the credit may 10 11 be claimed. Failure to comply with the foregoing provision 12 shall constitute a waiver of the right to claim the credit. (d) To qualify for this tax credit, a clinical trial 13 14 shall: (1) Meet the definition of a qualified clinical trial 15 specified in subsection (1); 16 17 Have qualified clinical trial costs totaling at least (2) 18 \$200,000; Provide evidence of reasonable efforts to hire local 19 (3) researchers and staff; and 20 (4) Provide evidence of financial or in-kind contributions 21 or educational or workforce development efforts, in 22

1	partnership with related trade and business
2	development organizations, educational institutions,
3	or both, toward the furtherance of the local science,
4	technology and health industry.
5	(e) On or after July 1, 2008, no qualified clinical trial
6	cost that has been financed by investments for which a credit
7	was claimed by any taxpayer pursuant to section 235-110.9 shall
8	be eligible for credits under this section.
9	(f) To receive the tax credit, the taxpayer shall first
10	pre-qualify the clinical trial for the credit by registering
11	with the department of taxation. Failure to comply with this
12	provision may constitute a waiver of the right to claim the
13	credit.
14	(g) The director of taxation shall prepare forms as may be
15	necessary to claim a credit under this section. The director
16	may also require the taxpayer to furnish information to
17	ascertain the validity of the claim for credit made under this
18	section and may adopt rules necessary to effectuate the purposes
19	of this section pursuant to chapter 91.
20	(h) Every taxpayer claiming a tax credit under this
21	section for a qualified clinical trial, no later than ninety
22	days following the end of each taxable year in which qualified
	2008-1059 SB3236 SD1 SMA.doc

1	clinical	trial costs were expended, shall submit a written,
2	sworn sta	tement to the department of taxation, identifying:
3	<u>(1)</u>	All qualified clinical trial costs as provided by
4		subsection (a), if any, incurred in the previous
5		taxable year;
6	(2)	The amount of tax credits claimed pursuant to this
7		section, if any, in the previous taxable year; and
8	(3)	The number of total hires versus the number of local
9		hires by category (i.e., department) and by county.
10	<u>(i)</u>	The department of taxation shall:
11	(1)	Maintain records of the names of the taxpayers and
12		qualified clinical trials thereof claiming the tax
13		<pre>credits under subsection (a);</pre>
14	(2)	Obtain and total the aggregate amounts of all
15		qualified clinical trial costs per qualified clinical
16		trial and per qualified clinical trial per taxable
17		year; and
18	(3)	Provide a letter to the director of taxation
19		specifying the amount of the tax credit per qualified
20		clinical trial for each taxable year that a tax credit
21		is claimed and the cumulative amount of the tax credit
22		for all years claimed.

- 1 Upon each determination required under this subsection, the
- 2 department of taxation shall issue a letter to the taxpayer,
- 3 regarding the qualified clinical trial, specifying the qualified
- 4 clinical trial costs and the tax credit amount qualified for in
- 5 each taxable year a tax credit is claimed. The taxpayer for
- 6 each qualified clinical trial shall file the letter with the
- 7 taxpayer's tax return for the qualified clinical trial to the
- 8 department of taxation. The director of taxation may audit and
- 9 adjust the tax credit amount to conform to the information filed
- 10 by the taxpayer.
- 11 (j) Total tax credits claimed per qualified clinical trial
- 12 shall not exceed \$8,000,000.
- (k) Qualified clinical trials shall comply with
- 14 subsections (d), (e), (f), and (h).
- (1) For the purposes of this section:
- "Qualified clinical trials" means a research study,
- 17 conducted within the State, to answer specific questions about
- 18 vaccines, new therapies or new ways of using known treatments to
- 19 determine whether new drugs or treatments are both safe and
- 20 effective.
- 21 "Qualified clinical trial costs" means the costs incurred
- 22 by a qualified clinical trial within the State that are subject

2008-1059 SB3236 SD1 SMA.doc

- 1 to the general excise tax under chapter 237 or income tax under 2 this chapter and that have not been financed by any investments 3 for which a credit was or will be claimed pursuant to section 4 235-110.9. Qualified clinical trial costs include but are not 5 limited to: 6 (1) Costs associated with planning, designing, executing, 7 and analyzing a qualified clinical trial; 8 Data, blood, and tissue sampling and analysis, (2) 9 statistical analysis; Hospital, physician, and nursing costs; 10 (3) 11 Wages or salaries of researchers and staff; (4)12 Costs of imaging and related technical services; (5) Costs associated with clinical trial participants; 13 (6) 14 (7) Rentals and fees for use of local facilities and research laboratories; and 15 Other direct clinical trial costs specified by the 16 (8) 17 department in consultation with the department of 18 taxation." SECTION 3. New statutory material is underscored. 19 SECTION 4. This Act, upon its approval, shall apply to 20
 - 2008-1059 SB3236 SD1 SMA.doc

taxable years beginning after December 31, 2007.

21

Report Title:

Clinical Trials; Tax Credit

Description:

Provides for an income tax credit amounting to fifteen per cent of qualified clinical trials incurred, in any county of Hawaii with a population over 700,000, and twenty per cent in any county with a population of 700,000 or less. Establishes criteria to qualify for the tax credit. Caps credit at \$8,000,000 per clinical trial. (SD1)